7doo: Difference between revisions
m Protected "7doo" [edit=sysop:move=sysop] |
No edit summary |
||
| Line 1: | Line 1: | ||
==Crystal Structure of PenA beta-Lactamase-Avibactam Complex== | ==Crystal Structure of PenA beta-Lactamase-Avibactam Complex== | ||
<StructureSection load='7doo' size='340' side='right'caption='[[7doo]]' scene=''> | <StructureSection load='7doo' size='340' side='right'caption='[[7doo]], [[Resolution|resolution]] 1.60Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7DOO OCA]. For a <b>guided tour on the structure components</b> use [ | <table><tr><td colspan='2'>[[7doo]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Burkholderia_multivorans_ATCC_17616 Burkholderia multivorans ATCC 17616]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7DOO OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7DOO FirstGlance]. <br> | ||
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.6Å</td></tr> | ||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=NXL:(2S,5R)-1-FORMYL-5-[(SULFOOXY)AMINO]PIPERIDINE-2-CARBOXAMIDE'>NXL</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7doo FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7doo OCA], [https://pdbe.org/7doo PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7doo RCSB], [https://www.ebi.ac.uk/pdbsum/7doo PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7doo ProSAT]</span></td></tr> | |||
</table> | </table> | ||
== Function == | |||
[https://www.uniprot.org/uniprot/A0A0H3KN52_BURM1 A0A0H3KN52_BURM1] | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Burkholderia multivorans is a significant health threat to persons with cystic fibrosis (CF). Infections are difficult to treat as this pathogen is inherently resistant to multiple antibiotics. Susceptibility testing of isolates obtained from CF respiratory cultures revealed that single agents selected from different antibiotic classes were unable to inhibit growth. However, all isolates were found to be susceptible to ceftazidime when combined with the novel non-beta-lactam beta-lactamase inhibitor, avibactam (all minimum inhibitor concentrations (MICs) were </=8 mg/L of ceftazidime and 4 mg/L of avibactam). Furthermore, a major beta-lactam resistance determinant expressed in B. multivorans, the class A carbapenemase, PenA was readily inhibited by avibactam with a high k2/K of (2 +/- 1) x 10(6) muM(-1) s(-1) and a slow koff of (2 +/- 1) x 10(-3) s(-1). Mass spectrometry revealed that avibactam formed a stable complex with PenA for up to 24 h and that avibactam recyclized off of PenA, re-forming the active compound. Crystallographic analysis of PenA-avibactam revealed several interactions that stabilized the acyl-enzyme complex. The deacylation water molecule possessed decreased nucleophilicity, preventing decarbamylation. In addition, the hydrogen-bonding interactions with Lys-73 were suggestive of a protonated state. Thus, Lys-73 was unlikely to abstract a proton from Ser-130 to initiate recyclization. Using Galleria mellonella larvae as a model for infection, ceftazidime-avibactam was shown to significantly (p < 0.001) improve survival of larvae infected with B. multivorans. To further support the translational impact, the ceftazidime-avibactam combination was evaluated using susceptibility testing against other strains of Burkholderia spp. that commonly infect individuals with CF, and 90% of the isolates were susceptible to the combination. In summary, ceftazidime-avibactam may serve as a preferred therapy for people that have CF and develop Burkholderia spp. infections and should be considered for clinical trials. | |||
Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients.,Papp-Wallace KM, Becka SA, Zeiser ET, Ohuchi N, Mojica MF, Gatta JA, Falleni M, Tosi D, Borghi E, Winkler ML, Wilson BM, LiPuma JJ, Nukaga M, Bonomo RA ACS Infect Dis. 2017 Jul 14;3(7):502-511. doi: 10.1021/acsinfecdis.7b00020. Epub , 2017 Mar 30. PMID:28264560<ref>PMID:28264560</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
<div class="pdbe-citations 7doo" style="background-color:#fffaf0;"></div> | |||
==See Also== | |||
*[[Beta-lactamase 3D structures|Beta-lactamase 3D structures]] | |||
== References == | |||
<references/> | |||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Burkholderia multivorans ATCC 17616]] | |||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Bonomo RA]] | [[Category: Bonomo RA]] | ||
[[Category: Nukaga M]] | [[Category: Nukaga M]] | ||
[[Category: Papp-Wallace KM]] | [[Category: Papp-Wallace KM]] | ||
Latest revision as of 19:37, 29 November 2023
Crystal Structure of PenA beta-Lactamase-Avibactam ComplexCrystal Structure of PenA beta-Lactamase-Avibactam Complex
Structural highlights
FunctionPublication Abstract from PubMedBurkholderia multivorans is a significant health threat to persons with cystic fibrosis (CF). Infections are difficult to treat as this pathogen is inherently resistant to multiple antibiotics. Susceptibility testing of isolates obtained from CF respiratory cultures revealed that single agents selected from different antibiotic classes were unable to inhibit growth. However, all isolates were found to be susceptible to ceftazidime when combined with the novel non-beta-lactam beta-lactamase inhibitor, avibactam (all minimum inhibitor concentrations (MICs) were </=8 mg/L of ceftazidime and 4 mg/L of avibactam). Furthermore, a major beta-lactam resistance determinant expressed in B. multivorans, the class A carbapenemase, PenA was readily inhibited by avibactam with a high k2/K of (2 +/- 1) x 10(6) muM(-1) s(-1) and a slow koff of (2 +/- 1) x 10(-3) s(-1). Mass spectrometry revealed that avibactam formed a stable complex with PenA for up to 24 h and that avibactam recyclized off of PenA, re-forming the active compound. Crystallographic analysis of PenA-avibactam revealed several interactions that stabilized the acyl-enzyme complex. The deacylation water molecule possessed decreased nucleophilicity, preventing decarbamylation. In addition, the hydrogen-bonding interactions with Lys-73 were suggestive of a protonated state. Thus, Lys-73 was unlikely to abstract a proton from Ser-130 to initiate recyclization. Using Galleria mellonella larvae as a model for infection, ceftazidime-avibactam was shown to significantly (p < 0.001) improve survival of larvae infected with B. multivorans. To further support the translational impact, the ceftazidime-avibactam combination was evaluated using susceptibility testing against other strains of Burkholderia spp. that commonly infect individuals with CF, and 90% of the isolates were susceptible to the combination. In summary, ceftazidime-avibactam may serve as a preferred therapy for people that have CF and develop Burkholderia spp. infections and should be considered for clinical trials. Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients.,Papp-Wallace KM, Becka SA, Zeiser ET, Ohuchi N, Mojica MF, Gatta JA, Falleni M, Tosi D, Borghi E, Winkler ML, Wilson BM, LiPuma JJ, Nukaga M, Bonomo RA ACS Infect Dis. 2017 Jul 14;3(7):502-511. doi: 10.1021/acsinfecdis.7b00020. Epub , 2017 Mar 30. PMID:28264560[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||